BWAY - Wutah dodolan YoY (TTM) BrainsWay

Stable cash flows at BrainsWay Ltd. are supported by the diversified distribution of neurostimulators. Annual operating revenue growth (TTM) confirms this resilience, and 31.90 becomes the new value for this metric. High R&D expenditures and H-coil patents block competitor entry, although pressure is mounting from new antidepressants and medtech behemoths in the growing non-invasive therapy niche.
BrainsWay - rincian analitis lan metrik utama (BWAY)

For BrainsWay Ltd., whose neurostimulation systems remain in demand regardless of economic cycles, this metric reflects the real dynamics of market demand for TMS therapy. By analyzing the LTM sales volume trend, an investor can see the consensus revenue estimate for the trailing twelve months, which allows for the identification of dangerous discrepancies between actual sales and accounting profit, thereby minimizing the risk of capital losses.